Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Ultrasound Screening of the Aorta in Giant Cell Arteritis (GCA-PANIC)

GCA Panic - Giant Cell Arteritis: Predicting Aneurysms in Clinics

The goal of this observational study is to find out whether ultrasound can reliably detect dilatation and aneurysms of the aorta, the main blood vessel that carries blood from the heart to the rest of the body, in people with giant cell arteritis (GCA). GCA causes inflammation in the blood vessel walls. It can affect the aorta and increase the risk of aortic dilatation and aneurysms. Aortic dilatation is an abnormal widening of the aorta. When it becomes large, it is called an aneurysm, and can lead to serious complications.

The main questions the study aims to answer are:

How accurately can ultrasound performed by rheumatologists detect dilatation and aneurysms of the aorta compared with computed tomography (CT) angiography, which provides detailed images of the aorta?

How consistently do different rheumatologists evaluate the aorta using ultrasound?

How often is aortic dilatation and aneurysms found in people with GCA who previously had signs of inflammation in the aorta on a PET-CT scan?

Researchers will compare ultrasound measurements with CT angiography findings to assess how well ultrasound detects aortic dilatation and aneurysms.

The study will include 102 participants: 82 people with GCA and previous signs of aortic inflammation on PET-CT, 10 people with GCA and a known aortic dilatation or aneurysm, and 10 people with aortic dilatation or aneurysm not caused by inflammation.

Participants will undergo an ultrasound examination of the ascending aorta, the part of the aorta closest to the heart. Participants will also undergo CT angiography of the aorta, which uses X-rays and contrast dye to produce detailed images of the blood vessel. The ultrasound measurements will be compared with the CT angiography findings. The ultrasound evaluations of the ultrasound performing rheumatologists will be compared with evaluations of a blinded assessor.

The long-term aim is to determine whether ultrasound could be a useful, non-invasive screening method to help identify aortic dilatation and aneurysms in people with GCA.

Aperçu de l'étude

Statut

Pas encore de recrutement

Type d'étude

Observationnel

Inscription (Estimé)

102

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Enfant
  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon non probabiliste

Population étudiée

GCA patients will be recruited from the five Rheumatology clinics of the Region of Southern Denmark (Odense University Hospital, Svendborg Hospital, Esbjerg Hospital, the Danish Hospital for Rheumatic Diseases, Lillebælt Hospital). Non-GCA patients will be recruited from the Cardiology clinic of Esbjerg Hospital.

La description

Inclusion Criteria:

  • GCA diagnosis with initial PET-CT involvement of thoracic aorta for the "GCA without known dilatation or aneurysm of the aorta" cohort
  • Established ascending aortic dilatation or anerysm through CT or MR angiography of the aorta and a history of GCA for the "GCA with known dilatation or aneurysm of the aorta" cohort
  • Established ascending aortic dilatation or aneurysm through CT or MR angiography of the aorta and no history of vasculitis for the "Non-GCA with known dilatation or aneurysm of the aorta" cohort

Exclusion Criteria:

  • Inability to consent
  • Inability to undergo ultrasound of the aorta
  • BMI ≥ 40
  • Previous operation for aortic structural damage

Specifically for the "GCA without known dilatation or aneurysm of the aorta" cohort:

  • Inability to undergo CT angiography of the aorta
  • Unknown kidney function and unwillingness to have it tested before CT angiography
  • Known kidney failure (eGFR<30ml/min/1.73m3)

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Modèles d'observation: COHORT
  • Perspectives temporelles: PROSPECTIVE

Cohortes et interventions

Groupe / Cohorte
GCA without known aortic dilatation or aneurysm but known aortic inflammation in PET-CT at debut

GCA patients with involvement of the thoracic aorta in the initial PET-CT upon diagnosis who have or have had regular follow-ups in the Rheumatology Clinics of the Region of Southern Denmark, who do not have known aortic dilatation or aneurysm, will be invited to participate in the study. These participants will undergo ultrasound of the proximal aorta and CT angiography of the aorta. Inclusion will stop at 82 subjects.

GCA with known aortic dilatation or aneurysm

GCA patients with CT or MR angiography-established dilatation or aneurysm of the thoracic aorta who have or have had regular follow-ups in the Rheumatology clinics of the Region of Southern Denmark will be invited to participate in the study. These participants will undergo ultrasound of the proximal aorta. Inclusion will stop at 10 subjects

Non-GCA with known aortic dilatation or aneurysm

Patients with CT or MR angiography established dilatation or aneurysm of the thoracic aorta on a non-inflammatory basis who have regular follow-ups in the Cardiology Clinic in Esbjerg Hospital will be invited to the study. These participants will undergo ultrasound of the proximal aorta. Inclusion will stop at 10 subjects.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Diagnostic accuracy of thoracic aorta ultrasound for detecting aortic dilatation and aneurysms
Délai: At the baseline study visit.

The ability of ultrasound measurements of the thoracic aorta to identify aortic dilatation or aneurysms will be evaluated using CT angiography as the reference standard. A receiver operating characteristic (ROC) curve will be used to assess how well the ultrasound measurements distinguish between participants with and without aortic dilatation or aneurysms. Diagnostic performance will be summarized by calculating the area under the ROC curve (AUC).

At the baseline study visit.

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Agreement between assessors in ultrasound measurements of the thoracic aorta
Délai: At the baseline study visit.

Agreement between rheumatologists performing ultrasound examinations and an independent, blinded assessor will be evaluated by comparing their measurements of the thoracic aorta. Agreement will be quantified using the intraclass correlation coefficient (ICC), which indicates how closely the measurements agree. A two-way random-effects model assessing absolute agreement will be used (ICC[2,1]).

At the baseline study visit.
Prevalence of thoracic aortic dilatation and aneurysm in GCA patients with prior FDG-PET/CT-confirmed aortic uptake
Délai: At the baseline study visit.

The prevalence of thoracic aortic dilatation and aneurysm will be assessed among the patients with giant cell arteritis (GCA) and aortic FDG uptake on PET/CT at diagnosis. Thoracic aortic diameters will be measured with CT angiography and aortic dilatation and aneurysm will be classified according to prespecified diameter-based diagnostic criteria. Prevalence will be calculated as the number of participants meeting the criteria for aortic dilatation or aneurysm at the study assessment divided by the total number of this cohort's participants with evaluable CT angiography scans. Aortic dilatation and aneurysm will also be reported separately, where applicable.

At the baseline study visit.

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Stavros Chrysidis, MD PhD, University of Southern Denmark

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 mai 2027

Achèvement primaire (Estimé)

31 décembre 2029

Achèvement de l'étude (Estimé)

31 décembre 2029

Dates d'inscription aux études

Première soumission

3 novembre 2026

Première soumission répondant aux critères de contrôle qualité

10 novembre 2026

Première publication (Réel)

16 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

16 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

10 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner